25I-NBMD (NBMD-2C-I, Cimbi-29) is a derivative of the
phenethylamine
Phenethylamine (PEA) is an organic compound, natural monoamine alkaloid, and trace amine, which acts as a central nervous system stimulant in humans. In the brain, phenethylamine regulates monoamine neurotransmission by binding to trace amin ...
hallucinogen
Hallucinogens are a large, diverse class of psychoactive drugs that can produce altered states of consciousness characterized by major alterations in thought, mood, and perception as well as other changes. Most hallucinogens can be categorized ...
2C-I
2C-I is a psychedelic phenethylamine of the 2C family. It was first synthesized by Alexander Shulgin and described in his 1991 book '' PiHKAL'' (''Phenethylamines I Have Known and Loved''). The drug has been used recreationally as psychedelic and ...
, discovered in 2006 by a team at
Purdue University
Purdue University is a public land-grant research university in West Lafayette, Indiana, and the flagship campus of the Purdue University system. The university was founded in 1869 after Lafayette businessman John Purdue donated land and money ...
led by
David Nichols. It acts as a potent
partial agonist
In pharmacology, partial agonists are drugs that bind to and activate a given receptor, but have only partial efficacy at the receptor relative to a full agonist. They may also be considered ligands which display both agonistic and antagonistic e ...
for the
5HT2A receptor
Receptor may refer to:
* Sensory receptor, in physiology, any structure which, on receiving environmental stimuli, produces an informative nerve impulse
*Receptor (biochemistry), in biochemistry, a protein molecule that receives and responds to a ...
with a
Ki of 0.049 nM at the human 5HT
2A receptor. The corresponding 4-bromo analogue 25B-NBMD has been used for molecular dynamics studies on the shape of the 5-HT
2A receptor.
Legality
Sweden
The Riksdag added 25I-NBMD to
Narcotic Drugs Punishments Act under ''swedish schedule I'' (''"substances, plant materials and fungi which normally do not have medical use"'') as of January 16, 2015, published by
Medical Products Agency (MPA) in regulation ''LVFS 2014:11'' listed as 25I-NBMD, and 2-(4-jodo-2,5-dimetoxifenyl)-N-
2,3-metylendioxifenyl)metyltanamin.
United Kingdom
Analogues and derivatives
References
25-NB (psychedelics)
Benzodioxoles
Designer drugs
Iodoarenes
Serotonin receptor agonists
{{hallucinogen-stub